GeneDx Smashes $100M Revenue, Expands Genomic Testing

GeneDx Achieves Record Revenue, Expands Genomic Testing in Rare Diseases GeneDx reported a significant milestone in Q2 2025, surpassing $100 million in revenue for the first time, with a 49% year-over-year increase. The companys core business in epilepsy, autism, and developmental delays, along with new areas like cerebral palsy, drove this growth. GeneDx now holds an 80% market share among geneticists in genomic testing for rare diseases. The companys expansion includes pushing into neonatal intensive care units (NICUs), where fewer than 5% of babies get tested despite a $1 billion opportunity. GeneDx has secured orders from 42 of the top 50 NICUs. Reimbursement rates have increased to over $3,700 per test, thanks to better payer policies and fewer denials. GeneDxs focus on transforming healthcare is evident in their rapid diagnostic capabilities, shifting from reactive to proactive care and reducing unnecessary suffering for children with rare conditions. The company boasts the worlds largest dataset with over 850,000 exomes, 7 million data points, and AI-powered platforms that identify over 500 gene-disease links. Looking ahead, GeneDx raised full-year guidance to $400-$415 million in total revenue, with exome and genome tests expected to grow by 48-52% and at least a 30% volume increase. The company is exploring general pediatrics, newborn screening, and pharma partnerships to fuel further growth. With momentum building in NICUs, new specialists, and state coverages now at 35 for outpatient, GeneDx is well-positioned to expand access to life-changing genomic insights while maintaining profitability. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7c77f765860198f8